Unicycive Therapeutics, Inc (UNCY) - מקדם חוב לטווח ארוך להון

The current long-term debt-to-equity trend and the level of 0.00, reflecting recent values, highlight the management strategy of Unicycive Therapeutics (UNCY) to optimize the budget and kidney therapy. Drug production has been outsourced to external CDMO centers to eliminate downtime. Simultaneously, automated molecule screening systems are being implemented, accelerating laboratory research into pathologies.

Unicycive Therapeutics (UNCY) is investing in the development of innovative hyperphosphatemia therapies to simplify patient treatment regimens. The historical long-term debt-to-equity ratio reflects the company's reliance on external borrowings with maturities exceeding one year relative to its own equity. This metric measures financial leverage, determining the degree of debt load used to fund R&D. The trend of this indicator helps assess the stability of the balance sheet structure. This asset belongs to the high-risk biotechnology sector.